Share chart Assembly Biosciences, Inc.
Extended chart
Simple chart
About
Assembly Biosciences, Inc. работает как биотехнологическая компания на клинической стадии в Соединенных Штатах. Компания разрабатывает оральные терапевтические кандидаты для лечения инфекции вируса гепатита B (HBV). Его продукты-кандидаты включают Вебикорвир для лечения пациентов с хронической инфекцией HBV; ABI-H2158, который находится в фазе II клинического исследования хронической инфекции HBV; ABI-H3733, который завершил клиническое исследование фазы Ia для лечения HBV. Компания имеет соглашения о сотрудничестве с Allergan Pharmaceuticals International Limited; BeiGene, Ltd .
More details| P/S | 32.55 |
|---|---|
| P/BV | 1.9 |
| EV/EBITDA | -4.75 |
| EBITDA | -0.1022 |
| Цена ао | 17.71 |
| Сайт | https://www.assemblybio.com |
| Число акций ао | 0.00458 млрд |
| Выручка | 0.016 |
| Див.доход ао | 0 |
| ISIN | US0453961080 |
| Валюта | usd |
| IPO date | 2010-12-17 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Change price per day: | +0.3399% (17.65) |
|---|---|
| Change price per week: | +10.69% (16) |
| Change price per month: | -3.49% (18.35) |
| Change price per 3 month: | +18.15% (14.99) |
| Change price per half year: | +32.07% (13.41) |
| Change price per year: | +1 316.8% (1.25) |
| Change price per 3 year: | +447.45% (3.235) |
| Change price per 5 year: | +16.13% (15.25) |
| Change price per year to date: | +2 611.68% (0.6531) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Vanguard Group Inc | 194923 | 3.56 |
| Millennium Management LLC | 120837 | 2.2 |
| Blackrock Inc. | 78998 | 1.44 |
| Anson Funds Management LP | 59956 | 1.09 |
| Geode Capital Management, LLC | 51000 | 0.93 |
| Renaissance Technologies, LLC | 35876 | 0.65 |
| Federated Hermes, Inc. | 25394 | 0.46 |
| Acuitas Investments LLC | 22132 | 0.4 |
| Bridgeway Capital Management, Inc. | 14500 | 0.26 |
| State Street Corporation | 12111 | 0.22 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.01708 | 36.318555985322 | 1.54048 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer | 664.4k | 1972 (52 years) |
| Mr. Jason A. Okazaki | CEO, President & Director | 869.28k | 1976 (48 years) |
| Dr. Adam Zlotnick | Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board | N/A | |
| Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer | N/A | |
| Dr. Uri A. Lopatin M.D. | Co-Founder and Clinical & Scientific Advisor | 608.55k | 1972 (52 years) |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | N/A | |
| Jeanette M Bjorkquist | Executive Director of Accounting & Treasury | N/A | |
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer | N/A | |
| Mr. Thomas E. Rollins | Executive Officer | 472.55k | 1956 (68 years) |
| Dr. Anuj Gaggar M.D., Ph.D. | Chief Medical Officer | N/A | 1978 (46 years) |
Address: United States, South San Francisco, CA , 331 Oyster Point Boulevard - open in Google maps, open in Yandex maps
Website: https://www.assemblybio.com
Website: https://www.assemblybio.com
